# Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD

> **NCT07046338** · NA · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 10 (estimated)

## Conditions studied

- Metachromatic Leukodystrophy (MLD)

## Interventions

- **GENETIC:** Lentiviral TYF-ARSA correction of patient's autologous HSCs

## Key facts

- **NCT ID:** NCT07046338
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2030-09-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07046338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07046338, "Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07046338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*